Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
复制标题
DOI：
10.1038/bjc.2017.70
复制
发表时间：
2017-04-01
影响因子：
8.8
通讯作者：
Daud, Adil
中科院分区：
文献类型：
--
作者：
Nosrati, Adi;Tsai, Katy K.;Daud, Adil
背景：抗PD-1治疗在晚期黑色素瘤中显示出显著的临床活性。我们开发并验证了一个临床预测量表的响应抗PD-1 monitoring.Methods：共315例晚期黑色素瘤患者与帕博利珠单抗（2或10 mg kg（-1）Q2 W或Q3 W）或纳武单抗（3 mg kg（-1）Q2 W）在2011年至2013年之间的四个癌症中心作为本队列研究的设置。将单因素分析中与缓解显著相关的变量输入前向逐步Logistic回归模型，并根据OR值进行评分，计算临床预测量表。
Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti-PD-1 monotherapy.Methods: A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10mg kg(-1) Q2W or Q3W) or nivolumab (3 mg kg(-1) Q2W) at four cancer centres between 2011 to 2013 served as the setting for the present cohort study. Variables with significant association to response on a univariate analysis were entered into a forward stepwise logistic regression model and were given a score based on ORs to calculate a clinical prediction scale.Results: The developed clinical prediction scale included elevated LDH (1 point), age